2VF0 Stock Chart & Stats
€0.03
<€0.01(16.67%)
At close: 4:00 PM EDT
€0.03
<€0.01(16.67%)
Day’s Range― - ―
52-Week Range€0.02 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.41M
Enterprise Value€14.23M
Total Cash (Recent Filing)€196.46K
Total Debt (Recent Filing)€3.56M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,441,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regenerative Medicine FocusA focused regenerative-medicine strategy gives Hemostemix a defined therapeutic direction in vascular and ischemic disease. Concentrating resources on patient-derived cell therapies may support technical specialization and clearer development priorities as clinical and regulatory work continues.
ACP-01 Clinical ProgramACP-01 addresses a serious vascular condition through a mechanism intended to improve blood flow, giving the core program a clinically meaningful objective. If development progresses, this focused candidate could provide a foundation for future commercialization and company growth.
Debt Below Prior PeakDebt not continuing to rise and remaining below its 2024 peak is a relative capital-structure strength. This may reduce incremental leverage pressure compared with a continually expanding debt burden, although the company’s overall balance sheet remains financially stressed.
Bears Say
Pre-Revenue BusinessThe absence of revenue shows that Hemostemix has not yet established commercial product sales, while negative gross profit confirms there is no operating revenue base absorbing development costs. Progress therefore remains dependent on advancing programs toward commercialization.
Negative EquityNegative equity and a very small asset base indicate limited balance-sheet resilience. This weak capital structure can constrain financial flexibility and increase the company’s exposure to refinancing or dilution as it funds clinical, regulatory, and operating requirements.
Worsening Cash BurnPersistently negative operating and free cash flow, combined with worsening burn, signals that the business is consuming cash rather than funding itself. Increasing funding needs can limit strategic flexibility and make continued progress reliant on external capital.
Hemostemix News
2VF0 FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was €0.02 and its highest was €0.08 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is €7.41M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Nov 27, 2026 which is in 32 days.
How were Hemostemix Inc’s earnings last quarter?
Hemostemix Inc released its earnings results on Aug 31, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 211,441,440 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Hemostemix Inc reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in DE:2VF0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.